1. Preface

   • Hidehiko Saito
   • Makoto Ogawa
   • Kaoru Shimokata

   EditorialNotes Pages: S1 - S1

2. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

   • Anthony L. Boral
   • Scott Dessain
   • Bruce A. Chabner

   Review Pages: S3 - S21

3. Overview of recent topics in clinical pharmacology of anticancer agents

   • Merrill J. Egorin

   Review Pages: S22 - S30

4. Clinical pharmacology of camptothecins

   • Lalitha Iyer
   • Mark J. Ratain

   Review Pages: S31 - S43

5. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

   • Yuichi Sugiyama
   • Yukio Kato
   • Xiao-yan Chu

   Original Article Pages: S44 - S49

6. Preclinical approach for identifying drug interactions

   • Tetsuya Kamataki
   • Tsuyoshi Yokoi
   • Yuichi Ando

   Original Article Pages: S50 - S53

7. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models

   • Edward A. Sausville
   • Richard D. Lush
   • Satoshi Kobayashi

   Original Article Pages: S54 - S59

8. High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer

   • Martin S. Tallman
   • William J. Gradishar

   Original Article Pages: S60 - S67

9. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients

   • Toru Watanabe

   Original Article Pages: S68 - S70

10. Combined-modality treatment for stage IIIa (n₂) non-small cell lung cancer: a national cancer institute intergroup study

    • David S. Ettinger

    Original Article Pages: S71 - S74

11. National Cancer Institute Clinical Trials Program in Colorectal Cancer

    • Barbara A. Conley
    • Richard S. Kaplan
    • Susan G. Arbuck

    Original Article Pages: S75 - S79

12. Clinical trials for advanced gastrointestinal cancers in Japan

    • Yasuhiro Shimada

    Original Article Pages: S80 - S84

13. The Cooperative Groups: Past and future

    • Robert L. Comis

    Original Article Pages: S85 - S87

14. Systems of protocol review, quality assurance, and data audit

    • Raymond B. Weiss

    Original Article Pages: S88 - S92

15. Cooperative oncology groups in Japan: Experience from the Japan Adult Leukemia Study Group

    • Ryuzo Ohno

    Original Article Pages: S93 - S97

16. European drug development and its impact on national activities: The Dutch example

    • Herbert M. Pinedo

    Original Article Pages: S98 - S101